Health care stocks were edging up Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.2%.
The iShares Biotechnology ETF (IBB) rose 0.5%.
In corporate news, Sonnet BioTherapeutics (SONN) shares surged past 47%. The company said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.
Kodiak Sciences (KOD) shares jumped 27% after Jefferies upgraded the company's rating to buy from hold. Jefferies also raised its price target for the stock to $20 from $6.
Revance Therapeutics (RVNC) and Crown Laboratories said Monday they amended their merger agreement to reduce Crown's tender offer for all outstanding Revance shares to $3.10 apiece in response to a dispute with Teoxane. Revance shares tumbled 20%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。